Greif Announces Start of its First Virtual Power Purchase Agreement (VPPA) in Europe
Under the 12-year agreement, Greif will purchase approximately 100 GWh per year of clean, renewable energy, helping the company offset an estimated 65% of its Scope 2 emissions in Europe and 3% of its combined Scope 1 and 2 emissions globally.
'The activation of our VPPA with Enel Green Power España and through Enel X Global Retail, is a testament to our commitment to reducing our environmental footprint and investing in sustainable solutions,' said Ole Rosgaard, President and CEO of Greif. 'This partnership not only advances our own sustainability objectives, but by funding the development of solar energy infrastructure, we are helping accelerate the world's transition to clean, renewable energy.'
The solar VPPA is a core component of the company's broader sustainability strategy, which is centered on reducing greenhouse gas emissions and minimizing waste throughout its operations. For more information about Greif's sustainability initiatives and the VPPA, please visit www.greif.com/sustainability.
About Greif, Inc.
Greif is a global leader in industrial packaging products and services, pursuing its vision to be the best customer service company in the world. The company produces steel, plastic and fiber drums, intermediate bulk containers, reconditioned containers, jerrycans and other small plastics, containerboard, corrugated sheets and products, uncoated recycled paperboard, coated recycled paperboard, tubes and cores, and a diverse mix of specialty products. Greif also manufactures packaging accessories and provides other packaging services for a wide range of industries. In addition, the company manages timber properties in the southeastern United States. Greif has a workforce of over 14,000 colleagues spread across more than 250 facilities in 37 countries to serve global as well as regional customers.
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Greif undertakes no obligation to update or revise any forward-looking statements.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
an hour ago
- National Post
Allianz Announces Excellent Performance and Is Fully on Track for Full-year Ambitions
MUNICH — 2Q 2025 Article content Allianz achieves strong growth and record operating profit Total business volume rises 8.0 1 percent to 44.5 billion euros, supported by good growth across all segments Operating profit increases 12.2 percent and reaches a record level of 4.4 billion euros, with particular strong contribution from the Property-Casualty segment Shareholders' core net income advances by 17.3 percent and reaches 3.0 billion euros. Adjusted for the 0.3 billion euros disposal gain on the UniCredit Joint Venture, shareholders' core net income increases 7.1 percent Article content 6M 2025 Article content Excellent performance across our businesses and record operating profit Total business volume grows 10.1 1 percent and reaches 98.5 billion euros, with contributions from all segments Operating profit increases 9.3 percent to 8.6 billion euros, our highest half-yearly operating profit ever, reaching 54 percent of our full-year outlook midpoint Shareholders' core net income advances 9.5 percent to 5.5 billion euros Core earnings per share grow 11.3 percent and reach 13.99 euros Annualized core RoE is excellent at 18.5 percent Adjusted for the one-off tax provision related to the forthcoming sale of our stake in our Indian Joint Ventures in 1Q and the disposal gain on the UniCredit Joint Venture in 2Q, shareholders' core net income increases strongly by 6.2 percent, core earnings per share rise 7.9 percent and our annualized core RoE is at a very strong level of 17.9 percent Solvency II capitalization ratio remains strong at 209 percent 2 with excellent capital generation Article content Outlook & other Article content 'Allianz has delivered record results in the first half of the year, underpinned by sustained growth and a disciplined focus on productivity. The value and relevance of our products help us to retain and expand our customer base. Article content Our diversified mix of businesses, global reach, and consistent execution bring opportunity and momentum, placing us on track to deliver on the ambitions set out at our Capital Markets Day in December.' Article content – Oliver Bäte, Chief Executive Officer of Allianz SE Article content FINANCIAL HIGHLIGHTS Article content Allianz Group: Excellent performance and record operating profit Article content Key performance indicator 2Q 2025 Change vs prior year 6M 2025 Change vs prior year Total business volume (€ bn) 4 44.5 8.0% 98.5 10.1% Operating profit (€ mn) 4,406 12.2% 8,644 9.3% Shareholders' core net income (€ mn) 2,976 17.3% 5,527 9.5% Core return on equity (annualized) (%) 5 18.5 1.6%-p Solvency II ratio (%) 5 209 1%-p Article content 'The strength of our business model and Allianz's capacity for consistent delivery are evident in our record operating profit of 8.6 billion euros for the first six months of the year. Article content We generated healthy and profitable growth across all segments and continued to produce sustainable value for all stakeholders. Article content Our performance sets a strong foundation for the remainder of the year and we confidently affirm our full-year operating profit outlook of 16 billion euros plus or minus 1 billion euros.' Article content – Claire-Marie Coste-Lepoutre, Chief Financial Officer of Allianz SE Article content In 2Q 2025, Allianz has delivered an excellent performance, characterized by strong growth and a record operating profit. Article content Our total business volume reached 44.5 (2Q 2024: 42.6) billion euros, an internal growth of 8.0 percent. All segments contributed to this attractive growth. Article content Operating profit rose 12.2 percent and reached a record level of 4.4 (3.9) billion euros, 28 percent of our full-year outlook midpoint. Article content Shareholders' core net income advanced 17.3 percent to 3.0 (2.5) billion euros. This growth was driven by a higher operating profit and an improved non-operating result. Adjusted for the 0.3 billion euros disposal gain on the UniCredit Joint Venture, shareholders' core net income increased 7.1 percent. Article content Allianz's 6M 2025 results were excellent, delivering a record operating profit underpinned by double-digit internal growth. Article content Our total business volume expanded to 98.5 (6M 2024: 91.0) billion euros, an internal growth of 10.1 percent, with particular strong growth in our Life/Health segment. Article content Operating profit was excellent at 8.6 (7.9) billion euros, a strong increase of 9.3 percent. The Property-Casualty business was the main growth driver but all business segments contributed. Article content Shareholders' core net income advanced by 9.5 percent to a strong level of 5.5 (5.0) billion euros. Adjusted for a one-off tax provision related to the forthcoming sale of our stake in our Indian Joint Ventures in 1Q and the disposal gain on the UniCredit Joint Venture in 2Q, shareholders' core net income was up by 6.2 percent. Article content Core earnings per share (EPS) 6 amounted to 13.99 (12.57) euros, an increase of 11.3 percent. Adjusted for the above-mentioned one-off tax provision and disposal gain, core earnings per share rose 7.9 percent. Article content Allianz has delivered an excellent annualized core return on equity (RoE) 6 of 18.5 percent in 6M 2025 (full-year 2024: 16.9 percent). Adjusted for the effects of the one-off tax provision and disposal gain, the annualized core return on equity (RoE) was 17.9 percent. Article content This performance was achieved while we maintained a strong capitalization with a Solvency II ratio of 209 percent (1Q 2025: 208 percent), supported by excellent capital generation.
Globe and Mail
5 hours ago
- Globe and Mail
BP Earnings Call: Strong Gains Amid Challenges
BP plc. ((BP)) has held its Q2 earnings call. Read on for the main highlights of the call. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. BP's Earnings Call Reflects Strong Performance Amid Challenges BP's recent earnings call conveyed a generally positive sentiment, underscored by robust operational performance and significant exploration successes. The company reported increased earnings, successful divestments, cost reductions, and enhanced shareholder returns. However, challenges persist in certain segments, such as tight diesel margins and impairments in specific areas. Strong Upstream Performance BP showcased its strong upstream performance by bringing five new major oil and gas projects online and sanctioning four additional ones. The company also celebrated ten exploration discoveries, marking a remarkable year for discoveries, with the Bumerangue Block in Brazil standing out despite concerns over CO2 content. Increase in Underlying Earnings The earnings call highlighted a substantial increase in underlying earnings within BP's customers' business, which rose by approximately 50% compared to the previous year. This growth occurred despite challenging market conditions, showcasing BP's resilience and strategic prowess. Successful Divestments and Cost Reductions BP reported successful divestments, with expected proceeds reaching around $3 billion for the year. Additionally, the company achieved structural cost reductions of approximately $1.7 billion since early 2024, demonstrating its commitment to financial efficiency. Dividend Increase and Share Buyback Shareholders were pleased with BP's announcement of a dividend increase of 4% to $0.0832 per ordinary share. Furthermore, the company declared a $750 million share buyback for the second quarter, reinforcing its commitment to returning value to shareholders. Record Refining Availability BP achieved record refining availability of 96.4% for the quarter, the highest since 2006. This milestone reflects the company's operational excellence and ability to maintain high levels of efficiency. Challenging Diesel Margins Despite the positive developments, BP faced challenges with tight diesel margins in its TravelCenters of America business, which impacted profitability. This segment remains an area of concern for the company. Impairments in Customer and Products and Gas and Low Carbon Segments BP took several impairments related to decisions on hydrogen and biofuels projects in Australia, as well as in the gas and low carbon space concerning M&S. These impairments highlight the ongoing challenges in these segments. Forward-Looking Guidance Looking ahead, BP's guidance remains optimistic, with operational reliability reported at over 96% across both upstream and downstream sectors. The company is committed to its 12-quarter strategic plan, focusing on enhancing operational efficiency and shareholder value. BP aims to continue its momentum with new projects and exploration discoveries, despite the challenges in certain areas. In conclusion, BP's earnings call painted a picture of a company achieving strong operational and financial performance, while also navigating challenges in specific segments. The overall sentiment was positive, with significant achievements in exploration and shareholder returns, although certain areas require continued attention and improvement.
Globe and Mail
5 hours ago
- Globe and Mail
Chronic Lymphocytic Leukemia Pipeline Outlook Report 2025: Key 55+ Companies and Breakthrough Therapies Shaping the Future Landscape
DelveInsight's, 'Chronic Lymphocytic Leukemia Pipeline Insight 2025' report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Chronic Lymphocytic Leukemia (CLL) pipeline landscape. It covers the Chronic Lymphocytic Leukemia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Lymphocytic Leukemia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Chronic Lymphocytic Leukemia Pipeline Report to explore emerging therapies, key players, and future treatment landscapes @ Chronic Lymphocytic Leukemia Pipeline Outlook Report In July 2025, AstraZeneca announced a Phase IV study to evaluate the safety and tolerability of acalabrutinib (monotherapy, 100 mg orally [po], twice daily [bd]) compared to investigator's choice of treatment, in patients with CLL (TN or R/R) and moderate to severe cardiac impairment. All patients will have cardiac impairment as defined by LVEF of < 50%. In July 2025, BeiGene announced a study is to support the registration plan of sonrotoclax plus zanubrutinib treatment in participants with previously untreated CLL. This study is designed to assess the contribution of sonrotoclax to the efficacy outcome of the combination of zanubrutinib and sonrotoclax. In July 2025, AbbVie conducted a study doctors put the participants in 1 of 4 groups, called treatment arms. Participants will receive oral venetoclax in combination with intravenously (IV) infused obinutuzumab or oral acalabrutinib at in different dosing schemes as part of treatment. Approximately 120 adult participants with CLL who are being treated with venetoclax will be enrolled in the study in approximately 80 sites worldwide. DelveInsight's Chronic Lymphocytic Leukemia pipeline report depicts a robust space with 55+ active players working to develop 60+ pipeline therapies for Chronic Lymphocytic Leukemia treatment. The leading Chronic Lymphocytic Leukemia Companies such as Loxo Oncology, Oncternal Therapeutics, MingSight Pharmaceuticals, Nurix Therapeutics, Starton Therapeutics, TG Therapeutics, Bristol Myers Squibb, Novartis, Aprea Therapeutics, AstraZeneca, Genor Biopharma, Incyte Corporation, MorphoSys, Astex Therapeutics, Lava Therapeutics, Celgene Corporation, and others. Promising Chronic Lymphocytic Leukemia Therapies such as Obinutuzumab, Rituximab, Chlorambucil, Acalabrutinib, and others. Discover how the Chronic Lymphocytic Leukemia treatment paradigm is evolving. Access DelveInsight's in-depth Pipeline Analysis for a closer look at promising breakthroughs @ Chronic Lymphocytic Leukemia Clinical Trials and Studies Chronic Lymphocytic Leukemia Emerging Drugs Profile Pirtobrutinib: Loxo Oncology Pirtobrutinib is an investigational, oral, highly-selective, non-covalent Bruton's tyrosine kinase (BTK) inhibitor. BTK plays a key role in the B-cell antigen receptor, signaling pathway, which is required for the development, activation and survival of normal white blood cells, known as B-cells, and malignant B-cells. Pirtobrutinib was designed to reversibly bind BTK, deliver consistently high target coverage regardless of BTK turnover rate, preserve activity in the presence of the C481 acquired resistance mutations, and avoid off-target kinases that have complicated the development of both covalent and investigational non-covalent BTK inhibitors. The drug is currently being evaluated in Phase III stage of development for the treatment of chronic lymphocytic leukemia. Cirmtuzumab: Oncternal Therapeutics Cirmtuzumab is a first-in-class humanized monoclonal antibody that binds with high affinity to a biologically important epitope on ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1). ROR1 is a type 1 transmembrane protein, essential for fetal development that is expressed on the plasma membrane with an extracellular domain that is essential for ligand binding and signal transduction. Cirmtuzumab binds to many different types of cancer cells but does not recognize most normal adult tissues. Cirmtuzumab was developed at the University of California in San Diego based on the pioneering scientific research of Thomas Kipps, MD, Ph.D., and his colleagues at the Moores Cancer Center. Oncternal holds an exclusive worldwide license to develop and commercialize antibodies recognizing ROR1. The development of cirmtuzumab has been supported by the California Institute for Regenerative Medicine (CIRM), in recognition of the role of ROR1 in conferring stem cell-like properties to the cancer cells that express it. A Phase II clinical trial is evaluating Cirmtuzumab to treat CLL. MS-553: MingSight Pharmaceuticals MS-553 is a potent, highly selective, oral, non-covalent inhibitor of PKCβ, a signaling molecule immediately downstream of BTK and PLCγ2 in the B-cell receptor (BCR) pathway. As PKCβ is downstream of both BTK and PLCγ2, it has the potential to treat acquired BTK resistance mutations in either protein, a feature absent from many second-generation BTK inhibitors. In the preliminary results, MS-553 was generally well tolerated, with initial anti-tumor activity seen in the heavily pretreated population. Potent to full inhibition of PKCβ signaling over 24 hours of exposure has been demonstrated. Additional dosing of patients will be completed to further assess MS-553 efficacy in patients with acquired resistance mutations in BTK and PLCG2. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of CLL. NX-2127: Nurix Therapeutics NX-2127 is an oral small molecule that combines the activity of a targeted BTK degrader with the cereblon immunomodulatory activity of an IKZF degrader. Cereblon immunomodulatory drugs that induce degradation are IKZF1 and IKZF3. Preclinical data support the activity of NX-2127 in tumor models harboring either wild-type BTK or BTK with mutations conferring clinical resistance to FDA-approved agents. Studies in non-human primates confirm potent BTK degradation with once-daily oral dosing. NX-2127 is being tested in an ongoing Phase I trial for patients with chronic lymphocytic leukemia who have failed prior treatments. NX-5948: Nurix Therapeutics NX-5948 is an oral small molecule degrader of BTK. Preclinical data support the activity of NX-5948 in tumor models harboring either wild-type BTK or BTK with mutations conferring clinical resistance to leading FDA approved agents. NX-5948 lacks cereblon immunomodulatory activity and has demonstrated the ability to cross the blood-brain barrier in animal models. NX-5948 has also demonstrated activity in animal models of autoimmune disease. The drug is currently being evaluated in the Phase I stage of development for the treatment of chronic lymphocytic leukemia. The Chronic Lymphocytic Leukemia Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Lymphocytic Leukemia with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Lymphocytic Leukemia Treatment. Chronic Lymphocytic Leukemia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Chronic Lymphocytic Leukemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Lymphocytic Leukemia market Explore groundbreaking therapies and clinical trials in the Chronic Lymphocytic Leukemia Pipeline. Access DelveInsight's detailed report now! @ New Chronic Lymphocytic Leukemia Drugs Chronic Lymphocytic Leukemia Companies Loxo Oncology, Oncternal Therapeutics, MingSight Pharmaceuticals, Nurix Therapeutics, Starton Therapeutics, TG Therapeutics, Bristol Myers Squibb, Novartis, Aprea Therapeutics, AstraZeneca, Genor Biopharma, Incyte Corporation, MorphoSys, Astex Therapeutics, Lava Therapeutics, Celgene Corporation, and others. Chronic lymphocytic leukemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Intravenous Subcutaneous Oral Intramuscular Chronic Lymphocytic Leukemia Products have been categorized under various Molecule types such as Monoclonal antibody Small molecule Peptide Download DelveInsight's latest report to gain strategic insights into upcoming therapies and key developments @ Chronic Lymphocytic Leukemia Market Drivers and Barriers, and Future Perspectives Scope of the Chronic Lymphocytic Leukemia Pipeline Report Coverage- Global Chronic Lymphocytic Leukemia Companies- Loxo Oncology, Oncternal Therapeutics, MingSight Pharmaceuticals, Nurix Therapeutics, Starton Therapeutics, TG Therapeutics, Bristol Myers Squibb, Novartis, Aprea Therapeutics, AstraZeneca, Genor Biopharma, Incyte Corporation, MorphoSys, Astex Therapeutics, Lava Therapeutics, Celgene Corporation, and others. Chronic Lymphocytic Leukemia Therapies- Obinutuzumab, Rituximab, Chlorambucil, Acalabrutinib, and others. Chronic Lymphocytic Leukemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Chronic Lymphocytic Leukemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Which companies are leading the race in Chronic Lymphocytic Leukemia drug development? Find out in DelveInsight's exclusive Pipeline Report—access it now! @ Chronic Lymphocytic Leukemia Emerging Drugs and Major Companies Table of Contents Introduction Executive Summary Chronic lymphocytic leukemia: Overview Pipeline Therapeutics Therapeutic Assessment Chronic lymphocytic leukemia– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Pirtobrutinib: Loxo Oncology Drug profiles in the detailed report….. Mid Stage Products (Phase II) Cirmtuzumab: Oncternal Therapeutics Drug profiles in the detailed report….. Early Stage Products (Phase I) NX-2127: Nurix Therapeutics Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Products Chronic lymphocytic leukemia Key Companies Chronic lymphocytic leukemia Key Products Chronic lymphocytic leukemia- Unmet Needs Chronic lymphocytic leukemia- Market Drivers and Barriers Chronic lymphocytic leukemia- Future Perspectives and Conclusion Chronic lymphocytic leukemia Analyst Views Chronic lymphocytic leukemia Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
